Skip to content
Search

Latest Stories

Submit Guest Post

US health regulator approves Cipla’s inhalation solution

Shilpa Sharma
By Shilpa SharmaJun 24, 2021
Shilpa Sharma
See Full Bio

PHARMACEUTICAL major Cipla received final consent from the US health regulator for Arformoterol Tartrate inhalation solution.

The approved product is used to treat conditions like chronic bronchitis and emphysema in the US market.

The company has received final approval for its abbreviated new drug application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL from the United States Food and Drug Administration (US FDA), Cipla said in a regulatory filing on Wednesday (23).

It is a generic version of Sunovion Pharmaceuticals Inc's Brovana.

Brovana is used in maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Brovana had sales of around $438 million (£314m) in the US for the 12-month period ending April 2021.

The new product is available for shipping immediately, Cipla said.

ciplaus
Add EasternEye As Your Trusted Source
preferred source on google news

Related News

Sanjay Bhandari's extradition appeal opens in London
Business

Sanjay Bhandari's extradition appeal opens in London

Rupert Murdoch looks on as he walks on the day of the hearing on the contentious matter of succession of Rupert Murdoch's global television and publishing empire, in Reno, Nevada, US, September 23, 2024. (Photo: Reuters)
Business

Murdoch's bid to secure eldest son's control of media empire fails

Kamlesh Pattni faces UK sanctions for illicit gold trade
Business

Kamlesh Pattni faces UK sanctions for illicit gold trade

Sanjay Malhotra speaks during the 67th Foundation Day of the Directorate of Revenue Intelligence (DRI) in New Delhi on December 4, 2024. (Photo: Getty Images)
Business

India appoints Sanjay Malhotra as new central bank governor

EasternEye

More For You

Co-op layoff

Co-op is cutting costs and reducing its workforce as it targets £200m in savings.

iStock

Co-op cuts jobs as £50m rise in National Insurance bill hits costs

  • Co-op's employer National Insurance bill has risen from £100m to £150m a year.
  • The group is cutting jobs as part of a wider plan to save £200m.
  • Co-op reported a £92m loss in the first half, despite group sales rising 2.4 per cent.

Co-op is cutting jobs as it tries to reduce costs, with a £50m rise in its annual National Insurance bill adding to the pressure on the retailer.

The mutually owned group, which runs more than 2,300 food stores and around 800 funeral homes, said it is targeting £200m in savings as it deals with higher costs and the financial impact of last year's cyberattack.

Keep ReadingShow less